Cytodyn Inc (CYDY)

[MrGuru]

Sjacobs,

Absolutely. That was one of the questions I posed to NP in today's conference: Once the financial situation improves which conditions will be "prioritized" ??

We have a lot on our plate (I good problem to have).

In my perspective the potential problems with basket trial are mainly two:

1) Follow up: Things can get out of control with both, participation and follow up once treatment is started. The posible useful data that can be gathered is easily "tainted" if we are not extremely careful.

2) Dosage: So assume we use 700mg for BC and somebody comes and want to treat Pancreatic cancer. What is the appropriated dosage ?? Let's assume we go with 700mg and the drug does not work as expected , or there is an unexpected parallel result and is concluded that perhaps 700 mg is too much for Pancreatic condition of this patient.

NP is indeed trying to help. And, also Lero seems to be a Wonder-Drug, however, there must be some care taken with each patient. I am sure this is exactly what CYDY intends to do, however, it costs some good money to do it right.

The occupancy test will help a lot if implemented as the dosage issue will be better determined, or at least, there will be an educated guidance as of where to start. And if things go out of the median, we will know how to react and what happened. Simultaneously data will be gathered for the respective pivotal trials.

We have a long-exciting road ahead. And, without exaggerating, if Lero works we will be part of medical history.

Very soon we will hopefully have more confirming results.